The hUC-MSCs cell line CCRC-1 represents a novel, safe and high-yielding HDCs for the production of human viral vaccines

Chen, Ping; Zhang, Kehua; Na, Tao; Wang, Lin; Yin, Weidong; Yuan, Bao‐Zhu; Wang, Junzhi

doi:10.1038/s41598-017-11997-1

Cited by 9 publications

(6 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous studies have shown that hUC-MSCs have significant immune modulation and tissue repair functions due to their low immunogenicity [14][15][16]. As an ideal candidate for allogenic adoptive transfer therapy, hUC-MSCs have been shown to play a protective role in A/H5N1-associated acute lung injury [17].…”

Section: Introductionmentioning

confidence: 99%

Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells

et al. 2020

View full text Add to dashboard Cite

Background: COVID-19 is a highly infectious respiratory disease. No therapeutics have yet been proven effective for treating severe COVID-19. Objectives: To determine whether human umbilical cord mesenchymal stem cell infusion may be effective and safe for the treatment of severe COVID-19. Methods: Patients with severe COVID-19 were randomly divided into 2 groups: the standard treatment group and the standard treatment plus hUC-MSC infusion group. The incidence of progression from severe to critical illness, 28-day mortality, clinical symptom improvement, time to clinical symptom improvement, hematologic indicators including C-reactive protein, lymphocyte number, and interleukin 6, and imaging changes were observed and compared between the two groups. Measurements and main results: The incidence of progression from severe to critical illness and the 28-day mortality rate were 0 in the hUC-MSC treatment group, while 4 patients in the control group deteriorated to critical condition and received invasive ventilation; 3 of them died, and the 28-day mortality rate was 10.34%. In the hUC-MSC treatment group, the time to clinical improvement was shorter than that in the control group. Clinical symptoms of weakness and fatigue, shortness of breath, and low oxygen saturation obviously improved beginning on the third day of stem cell infusion and reached a significant difference on day 7. CRP and IL-6 levels were significantly lower from day 3 of infusion, the time for the lymphocyte count to return to the normal range was significantly faster, and lung inflammation absorption was significantly shorter on CT imaging in the hUC-MSC group than in the control group. Conclusions: Intravenous transplantation of hUC-MSCs is a safe and effective method that can be considered a salvage and priority treatment option for severe COVID-19.

show abstract

Section: Introductionmentioning

confidence: 99%

Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Numerous studies have shown hUC-MSCs play significant immune-modulation and tissue repair functions for its low immunogenicity [13][14][15]. As an ideal candidate for allogenic adoptive transfer therapy, hUC-MSCs have been shown to play a protect role in A/H5N1-associated acute lung injury [16], Although one article have been published recently on the therapeutic effects of stem cells on COVID-19, it is about bone marrow mesenchymal stem cells [17],and did not focus on the treatment of severe COVID-19.…”

Section: Introductionmentioning

confidence: 99%

Treatment of Severe COVID-19 with human Umbilical Cord Mesenchymal Stem Cells

Shu¹,

Niu

et al. 2020

Preprint

109

View full text Add to dashboard Cite

Background COVID-19 is a highly infectious respiratory disease. No effective therapeutics have yet been proved for treating of severe COVID-19. Objectives To determine whether human Umbilical Cord Mesenchymal Stem Cells infusion may be effectiveness and safety in the treatment of severe COVID-19. Methods The severe COVID-19 randomly divided into 2 groups, standard treatment group and standard treatment plus hUC-MSCs infusion group. The incidence of severe patients aggravated to critically illness, 28-day mortality, clinical symptoms improvement, time to clinical symptoms improvement, hematologic indicators including C-reaction protein, lymphocyte number, interleukin 6 and imaging changes were observed and compared between two groups. Measurements and Main Results The incidence of severe patients aggravated to critically illness and 28-day mortality were 0 in hUC-MSCs treatment group, while 4 patients in control group were deteriorated to critical illness and been used invasive ventilation, 3 of them died, and 28-day mortality was 10.34%. In hUC-MSCs treatment group, the time to clinical improvement was shorter, clinical symptoms of weakness and fatigue, shortness of breath, and low oxygen saturation had improved obviously began the third day of stem cells infusion, and reached the significant difference on the day 7, CRP and IL-6 were significantly decreased from day 3 of infusion, the time for lymphocyte count returned to normal range was significant faster, and lung inflammation absorption was significantly shorter from CT imaging. Conclusions Intravenous transplantation of hUC-MSCs is a safe and effective way that can be considered as salvage and priority choice in the treatment of severe COVID-19.

show abstract

“…In general, HUC-MSC treatment of viral diseases improves clinical symptoms by regulating the immune function of the patients. Importantly, HUC-MSCs are a safe and feasible source of human diploid cells (HDCs) for the production of antiviral vaccines [ 89 ].…”

Section: Main Textmentioning

confidence: 99%

What is the impact of human umbilical cord mesenchymal stem cell transplantation on clinical treatment?

et al. 2020

View full text Add to dashboard Cite

Background Human umbilical cord mesenchymal stem cells (HUC-MSCs) present in the umbilical cord tissue are self-renewing and multipotent. They can renew themselves continuously and, under certain conditions, differentiate into one or more cell types constituting human tissues and organs. HUC-MSCs differentiate, among others, into osteoblasts, chondrocytes, and adipocytes and have the ability to secrete cytokines. The possibility of noninvasive harvesting and low immunogenicity of HUC-MSCs give them a unique advantage in clinical applications. In recent years, HUC-MSCs have been widely used in clinical practice, and some progress has been made in their use for therapeutic purposes. Main body This article describes two aspects of the clinical therapeutic effects of HUC-MSCs. On the one hand, it explains the benefits and mechanisms of HUC-MSC treatment in various diseases. On the other hand, it summarizes the results of basic research on HUC-MSCs related to clinical applications. The first part of this review highlights several functions of HUC-MSCs that are critical for their therapeutic properties: differentiation into terminal cells, immune regulation, paracrine effects, anti-inflammatory effects, anti-fibrotic effects, and regulating non-coding RNA. These characteristics of HUC-MSCs are discussed in the context of diabetes and its complications, liver disease, systemic lupus erythematosus, arthritis, brain injury and cerebrovascular diseases, heart diseases, spinal cord injury, respiratory diseases, viral infections, and other diseases. The second part emphasizes the need to establish an HUC-MSC cell bank, discusses tumorigenicity of HUC-MSCs and the characteristics of different in vitro generations of these cells in the treatment of diseases, and provides technical and theoretical support for the clinical applications of HUC-MSCs. Conclusion HUC-MSCs can treat a variety of diseases clinically and have achieved good therapeutic effects, and the development of HUC-MSC assistive technology has laid the foundation for its clinical application.

show abstract

The hUC-MSCs cell line CCRC-1 represents a novel, safe and high-yielding HDCs for the production of human viral vaccines

Cited by 9 publications

References 33 publications

Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells

Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells

Treatment of Severe COVID-19 with human Umbilical Cord Mesenchymal Stem Cells

What is the impact of human umbilical cord mesenchymal stem cell transplantation on clinical treatment?

Contact Info

Product

Resources

About